

International Conference on **Pediatrics & Gynecology**

Treatment of disseminated breast cancer with multiple affection nidi

G. A. Khakimov, B. B. Negmajanov and F. I. Zokirov

Tashkent Pediatric Medical Institute, Uzbekistan

Breast cancer (BC) is the most common cause of cancer – related mortality in women. The main cause of mortality in this group is generalization of BC with development of polyorganic insufficiency in the background of chronic pain syndrome. In this connection the choice of rational methods of palliative therapy remains actual, especially in cases with multiple affection nidi.

Objective of the study was to evaluate the volume of palliative chemoradiation therapy implantation to increase the survival rate of patients.

To research were included 23 women with disseminated breast cancer (DBC) at the age of 34-60 years and they were divided into 2 groups: The 1st group consisted of 13 women with distant metastases in liver, bones of skeleton and skin. The 2nd group consisted of 10 women with metastases in supraclavicular lymph nodes of affected site, in liver and bones of skeleton. Patients of first group in the background of palliative polychemotherapy (PPCT) (4-6 cycles) – taxanes with anthracyclines, received shortfocal therapy in the region of intradermal metastases. Patients of second group received similar PPCT with palliative radiation therapy in supraclavicular region – 40-44 Gy. Patients of both group under control of blood Calcium levels received bisphosphonates.

In patients with DBC in both of group average time for disease progression as development of polyorganic insufficiency with sharp limitation of specialized therapy arsenal was 8.7 months. In addition to that local disease control – without signs of lymphostasis and limitations in volume of movement in upper extremity of affected site without impairment of patient's life quality was marked.

Implementation of palliative chemoradiation and X-ray therapy in patients with DBC allows to increase average time of disease progression and life quality of fatally diseased patients with DBC.

Biography

Khakimov Golib Abdullayevich: MD, Professor. Head of Department of Oncology in Tashkent Pediatric Medical Institute. Has published more than 100 papers in reputed journals.